Regenxbio's muscle disorder therapy meets main goal in late-stage study
14/05/2026 12:03
May 14 (Reuters) - Regenxbio RGNX.O said on Thursday that its experimental therapy to treat a muscle-wasting disorder met the main goal in a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics